Aegerion Pharmaceuticals Inc.

(AEGR) Trade

By |

Profile

Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc.

Contact Information

Website: www.aegerion.com
Main Phone: +1 617 500-7867
Address: One Main Street
Address 2: Suite 800
State: MA
City / Town: Cambridge
Country: USA
Postal Code: 02142

Issuer Information

Exchange: NGS
CEO: Mary T. Szela
Employees: 318
NAICS: Pharmaceutical Preparation Manufacturing(325412)
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume 0 52 Wk Hi 10.85 52 Wk Low 1.23
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 29,545,088.00 EPS (TTM) -5.98 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 0
Number of Buys 0 0
Number of Sells 0 0
Net Activity 0 0
Last 10 Buys Shares
Mark J. Fitzpatrick 1,000
Marc D. Beer 1,000
Marc D. Beer 1,000
Marc D. Beer 1,000
Marc D. Beer 1,000
Marc D. Beer 1,000
Anne M. Vanlent 1,000
Anne M. Vanlent 1,000
Marc D. Beer 1,000
Anne M. Vanlent 1,000
Last 10 Sell Shares
Craig Fraser 1,000
Craig Fraser 1,000
Craig Fraser 1,000
Mark Sumeray 1,000
Mark Sumeray 1,000
Mark Sumeray 1,000
Mark Sumeray 1,000
Mark Sumeray 1,000
Mark J. Fitzpatrick 1,000
Mark J. Fitzpatrick 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 1.5 1.5 1.5 1.5
Low Target Price Estimate 1.5 1.5 1.5 1.5
Mean Target Price Estimate 1.5 1.5 1.5 1.5
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 11/15/16 11/15/16 11/15/16 11/15/16
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 2 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 3 3 3 3